Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease
暂无分享,去创建一个
M. Ganji | L. Lerman | A. Lerman | C. Shi | E. Braggio | T. Lasho | M. Corban | Ali Ahmad | C. Finke | T. Toya | Zhuoer Xie | Xianfeng Chen | K. Stewart | Nadia Akhiyat | Jenna A. Fernandez | M. Patnaik
[1] A. Jaffe,et al. Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction , 2022, Journal of the American Heart Association.
[2] Andrew D. Johnson,et al. Clonal Hematopoiesis Is Associated With Higher Risk of Stroke , 2021, Stroke.
[3] U. Wagner,et al. Extracellular NLRP3 inflammasome particles are internalized by human coronary artery smooth muscle cells and induce pro-atherogenic effects , 2021, Scientific Reports.
[4] P. Natarajan,et al. Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. , 2021, Journal of molecular and cellular cardiology.
[5] Yi Xie,et al. TET2 Protects Against Vascular Smooth Muscle Cell Apoptosis and Intimal Thickening in Transplant Vasculopathy , 2021, Circulation.
[6] A. Dopazo,et al. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. , 2021, Journal of the American College of Cardiology.
[7] L. Lerman,et al. Coronary Microvascular Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Artery Disease Is Associated With Elevated Serum Homocysteine Levels , 2020, Journal of the American Heart Association.
[8] L. Lerman,et al. Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction , 2020, European journal of heart failure.
[9] G. Getz,et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant , 2020, Nature Communications.
[10] V. Murthy,et al. Association of Isolated Coronary Microvascular Dysfunction With Mortality and Major Adverse Cardiac Events: A Systematic Review and Meta‐Analysis of Aggregate Data , 2020, Journal of the American Heart Association.
[11] S. Gabriel,et al. Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis , 2019, Circulation.
[12] P. Libby,et al. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease , 2019, Nature Reviews Cardiology.
[13] R. Kwong,et al. Global Coronary Flow Reserve Measured During Stress Cardiac Magnetic Resonance Imaging Is an Independent Predictor of Adverse Cardiovascular Events. , 2019, JACC. Cardiovascular imaging.
[14] P. Libby,et al. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[15] M. Price,et al. The functional assessment of patients with non-obstructive coronary artery disease: expert review from an international microcirculation working group. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] P. Libby,et al. CHIPping Away at the Pathogenesis of Heart Failure. , 2019, JAMA cardiology.
[17] B. Brüne,et al. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure , 2018, JAMA cardiology.
[18] P. Libby,et al. CHIP (Clonal Hematopoiesis of Indeterminate Potential). , 2018, Circulation.
[19] Zuo Wang,et al. TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis. , 2018, DNA and cell biology.
[20] Fei Li,et al. Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to atherlosclerotic cardio/cerebro-vascular diseases? , 2018, Genes & diseases.
[21] D. Goukassian,et al. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome. , 2018, Journal of the American College of Cardiology.
[22] P. Libby,et al. The Present and FutureReview Topic of the WeekInterleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond , 2017 .
[23] S. Gabriel,et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.
[24] Matthew A. Cooper,et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.
[25] T. Druley,et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults , 2016, Nature Communications.
[26] R Jay Widmer,et al. Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease. , 2015, JACC. Cardiovascular interventions.
[27] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[28] Tetsuya Takahashi,et al. Endothelial dysfunction is associated with the severity of cerebral small vessel disease , 2015, Hypertension Research.
[29] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[30] Yu Jin,et al. Ten-Eleven Translocation-2 (TET2) Is a Master Regulator of Smooth Muscle Cell Plasticity , 2013, Circulation.
[31] J. Kaski,et al. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. , 2012, European heart journal.
[32] Koki Nakanishi,et al. Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[33] M. Rubens,et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. , 2009, European heart journal.
[34] F. Crea,et al. Coronary microvascular dysfunction. , 2013, The New England journal of medicine.
[35] A. Lerman,et al. The endothelium: Dysfunction and beyond , 2001, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[36] S. Higano,et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.
[37] S. Higano,et al. Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. , 1998, Mayo Clinic proceedings.